Contributors
Je a n -Ma rc Ai a c h e, 6 Cy nthia K. Brow n , 5 Je n n i fe r Dre s s m a n 3 , Ru z i ca Djerki , 7 Kirsti Gjellan 8 , Vi v i a n Gray, 9 Johannes Kra e m e r, 1 0 Henning Kri s te n s e n , 1 1
Ch ristian Le u n e r, 3 Pe t ra Loo s, 2 Helga Moe l l e r, 4 Be rndt Mu e l l e r, 1 2 Saeed Qu re s h i , 1 3 Jo s e p h Ro b i n s o n , 1 4 Vi n od P. Sh a h , 1 and Ma rtin Si e we rt .
2 * This article is re p re s e nting the conclusions fro m s eve ral ex pe rts and,in part i c u l a r,is deri ved from a s e ries of wo rkshops held under the auspices of FIP.
It is published as a dra ft position paper to inv i te co m m e nts from the scient i f i c,te c h n i cal and re g u l ato ry co m m u n i ty.FIP and AAPS will co -s ponsor a t h i rd wo rkshop in Se p te m ber 2002 after which,a n d including co m m e nts on this art i c l e,a final FIP po s ition paper will be published.
Please send co m m e nts to the Ch a i rman of the FIP Dissolution Wo rking Gro u p : Dr.Ma rtin Si e we rt Ave ntis Ph a rma AG Poseidon Bl d g.Room 942 D-65926 Fra n k f u rt am Ma i n Ge rm a ny e m a i l :m a rt i n . s i e we rt @ ave nt i s. co m f a x :+49 69 305 16692 1 Food and Drug Ad m i n i s t rat i o n ,Roc k v i l l e,M D 2 Ave ntis Ph a rm a , Fra n k f u rt, Ge rm a ny 3 JW Goethe Un i ve r s i ty, Fra n k f u rt, Ge rm a ny 4 Ze nt ra l l a bo rato rium Deutscher Apo t h e ke r, Es c h bo rn , Ge rm a ny 5 Qu i nt i l e s, I n c. Kansas Ci ty, M O 6 Un i ve s i te d' Au ve rg n e, Cl a rm o nt -Fe rrand Ce d ex , Fra n ce 7 Nova rtis Ph a rm a , Sw i t ze rl a n d 8 As t ra Ze n e ca , Sod e rt a l j e, Swe d e n 9 V. A .Gray Co n s u l t i n g, I n c. , Hoc ke s s i n ,D E 1 0 L a bo rato ry and Qu a l i ty Se rv i ce s, Es c h bo rn , Ge rm a ny 1 1 Un i ve r s i ty of Co pe n h a g e n , De n m a rk 1 2 Kiel Un i ve r s i ty, Ge rm a ny 1 3 Health Pro te ction Bra n c h , Ca n a d a 1 4 Un i ve r s i ty of Wi s co n s i n ,U S A I dx.doi.org/10.14227/DT090102P6 a p p l i ca b l e. In seve ral other instance s,e. g. ,chewing gums, powd e r s,g ra n u l e s,solid dispe r s i o n s, m i c ro p a rt i c l e s,a n d i m p l a nt s,m o re method deve l o p m e nt and re f i n e m e nt will be re q u i red be fo re a final re co m m e n d ation on standard i ze d d rug release methods can be made.For these dosage fo rm s, a brief summary of the state -o f -t h e -a rt kn owledge is p rovided to guide further deve l o p m e nt .Due to the diffe re nt c h a ra cte ristics of the special dosage fo rms and their site s and modes pf applicat i o n ,it is essential that apparatus select i o n ,co m position of the dissolution medium,a g i t ation (flow rate) and te m pe rat u re be given appro p ri ate co n s i d e rat i o n d u ring eva l u ation of key method para m e te r s. I n s t a n ce s w h e re a co m pendial (USP,Ph . Eu r. ,Ph . J a p.) basket or paddle m e t h od is employed for in vitro drug release te s t i n g,t h e ex pe ri m e ntal test co n d i t i o n s,q u a l i f i cations and va l i d at i o n s teps should be the same as discussed in the FIP Gu i d e l i n e s on dissolution testing (1).
Dosage Forms for Which a Specific Method Can Be Recommended

Oral Suspensions
In genera l ,the ro t ating paddle method utilizing an aqueous dissolution medium is the re commended method for dissolution testing of suspe n s i o n s.To obtain re p re s e nt at i ve samples,p rod u ct pre p a ration should fo l l ow a standardi zed proce d u re based on shaking or mixing.Sa m p l e we i g ht / volume should re f l e ct a ty p i cal dose of the prod u ct . Me t h od para m e ters such as sample int rod u ction and agitation rate should be established on the basis of the visco s i ty and co m position of the suspension mat ri x . The sample i nt rod u ction technique must be accurate,p recise and re p rod u c i b l e. The agitation rate should facilitate discri m i n ation be tween batches with diffe re nt release pro pe rt i e s. For low visco s i ty suspe n s i o n s,an accurate dose can be d e l i ve red to the bo t tom of the dissolution vessel using a vo l u m e t ric pipe t te.A low agitation rate of 25 rpm is generally re commended for less viscous suspensions (2). For high v i s co s i ty samples,the dose may need to be dete rmined by we i g ht with a quant i t at i ve sample tra n s fer to the dissolution vessel to ensure accura cy of the sample size int rod u ce d. High visco s i ty suspensions may also re q u i re a higher a g i t ation rate such as 50 or 75 rpm to preve nt sample mounding at the bo t tom of the ve s s e l .
Chewable Tablets
In pri n c i p l e,the test proce d u re employed for chewa b l e tablets should be the same as that for regular tablets. Th i s co n cept is based on the po s s i b i l i ty that a pat i e nt might s wa l l ow the dosage fo rm without pro per chewing,in which case the drug will still need to be released to ensure the d e s i red pharm a co l og i cal action (3). Wh e re applica b l e,te s t conditions would pre fe rably be the same as used fo r co nve ntional tablets of the same act i ve pharm a ce u t i ca l i n g re d i e nt,but be cause of the non-disinte g rating nat u re of the dosage fo rm ,t h e re may be a nece s s i ty to alter te s t conditions (e. g.i n c rease the agitation rate) and spe c i f i cations (e. g.i n c rease the test durat i o n ) .
Transdermal Patches
Although seve ral apparatus and proce d u res have be e n u t i l i zed to study in vitro release chara cte ristics of tra n sd e rmal patc h e s,it is desirable to avoid unnece s s a ry pro l i fe ration of dissolution test equipment . Cu rre nt co m pe n d i a l a p p a ratus include paddle over disk (USP apparatus 5), ro t ating cylinder (USP apparatus 6) and re c i p rocating disk (USP apparatus 7). As it has been shown ex pe ri m e ntally that a simple paddle over disk proce d u re using a watch glassp atc h -s c reen sandwich assembly results in almost the same release profile as other,m o re co m p l i cated apparatus for all US marke ted tra n s d e rmal patches (4) the paddle over disk p roce d u re with a watch glass-patc h -s c reen sandw i c h assembly is co n s i d e red method of choice.
The co n f i g u ration of this assembly ensures that the patc h is preve nted from floating during the ent i re testing pe ri od. Special at te ntion needs to be given to the pro per po s itioning of the patch so that the drug-loaded surf a ce is ex posed to the medium. The pH of the medium ideally should be adjusted to 5 -6,re f l e cting phys i o l og i cal ski n co n d i t i o n s.For the same re a s o n ,test te m pe rat u re is ty p ically set at 32°C.
Semisolid Dosage Forms
Semisolid dosage fo rms include cre a m s,o i nt m e nts and g e l s. In vitro drug release from semisolid dosage fo rms has been exte n s i vely inve s t i g ated using the Franz cell diffusion s ys tem (5) with a synthetic membrane and to some exte nt using the Enhancer cell (6).Co m p a rat i ve studies indicate t h at both ty pes of apparatus generate similar dat a . Howeve r,in ce rtain instance s,e s pecially with gels,the diffusion cell sys tem appears to have some supe ri o ri ty as re s u l t s a re less depe n d e nt on specific fo rm u l at i o n / co m po s i t i o n details (7).
De pending on the solubility of the drug substance,t h e re ce p tor medium may need to co ntain alcohol and/or s u rf a ct a nt .De -a e ration is cri t i cal to avoid bubble fo rm at i o n at the inte rf a ce with the membra n e.As with tra n sd e rmal prod u cts the test te m pe rat u re is ty p i ca l l y set at 32°C to re f l e ct the usual skin te m pe rat u re.
Suppositories
For hyd rophilic suppo s i to ries that release the dru g by dissolving in the re ctal fluids,the baske t,p a d d l e, or flow -t h rough cell can all be used in pri n c i p l e. For lipophilic suppo s i to ries that release the dru g a fter melting in the re ctal cav i ty,a modified baske t m e t h od is re co m m e n d e d.A paddle method with a w i red screen and a sinker is also re commended (8). For lipophilic suppo s i to ri e s,a modified flowt h rough cell with the specific suppo s i to ry cell has also been eva l u ate d.E x pe ri e n ce with this cell has s h own that it may generate highly va riable data due to the be h avior of the suppo s i to ry in the ce l l ,i n p a rticular for fo rm u l ations co ntaining spre a d i n g a g e nt s.Th e re fo re,this modified flow through ce l l with the specific suppo s i to ry cell cannot be re co mmended generally for quality co nt rol and ro u t i n e a n a l ysis of lipophilic suppo s i to ries (9).
Dosage Forms Requiring More Work Before a Method Can Be Recommended
Chewing Gum
In the case of chewing gums,the inte n s i ty and f re q u e n cy of shearing fo rce s / a ctivities (i.e. "c h e w i n g"a ction) can have a large influence on dru g release rate. The Eu ro pean Ph a rm a co poeia prov i d e s a description of an apparatus designed for testing of chewing gum prod u cts (10).Howeve r,to date there has been insufficient ex pe ri e n ce with this apparat u s to draw a firm conclusion about its suitability.
Powders, Granules, Solid Solutions and Solid Dispersions
The flow through apparatus offers specific sample cells for studying drug release from powder and g ranular dosage fo rm s.Howeve r,it is impo rt a nt to n o te that the dissolution be h avior of these dosage fo rms may be gre atly influenced by their we t t a b i l i ty, s u rf a ce area and particle size distri b u t i o n .Th u s,the in v i t ro release test results co n s t i t u te one of a group of p hys i coc h e m i cal para m e ters needed to chara cte ri ze the prod u ct .For powd e r s,e s pecially when ex h i b i t i n g poor we t t a b i l i ty,it may be nece s s a ry to add a surf a ct a nt to the dissolution medium to obtain re p roducible dissolution re s u l t s.Ca re should be taken to use a level of surf a ct a nt that does not increase the s o l u b i l i ty of the drug to the exte nt where the test is no longer discri m i n ato ry.
Solid solutions and dispersions may be housed in seemingly ty p i cal oral dosage fo rms such as capsules and tablets.If this is the ca s e,their in vitro release chara cte ristics can be dete rmined by m e t h ods ty p i cal for solid oral dosage fo rm s.Si n ce solid solutions and dispersions usually lead to a s u per sat u ration of the medium,it is often of inte re s t ( e s pecially during prod u ct deve l o p m e nt) to run the in vitro release test somewhat longer so that the po te ntial for pre c i p i t ation can be appra i s e d.
Parenterals: Implants and Microparticles
The modified flow -t h rough cell has been used s u c cessfully for implants and micro p a rt i c l e s. Th e co m pendial flow -t h rough apparatus is mod i f i e d with re g a rd to the inner diameter to suit the spe c i a l p ro pe rties for testing pare nte ra l s,i . e.l ow volume of a c ce p tor co m p a rt m e nt .The flow rate of the medium has to be set ve ry slow.As tests are ofte n run over a long time pe ri od (e. g.s eve ral we e k s ) m e a s u res have to be taken to co m pe n s ate against eva po ration and to preve nt microbial growth in the m e d i u m . The co m position of the medium should t a ke into co n s i d e ration the osmolari ty,pH and b u f fer ca p a c i ty of the fluids at the site of applicat i o n ,which are usually assumed to resemble that of p l a s m a .Howeve r,the main challenges with this ty pe of dosage fo rm are to dete rmine the approp ri ate duration of the test and the times at which samples are to be drawn in order to chara cte ri ze the release profile adequate l y.The po s s i b i l i ty of running the test under acce l e rated conditions is at t ra ct i ve,but to date there has not been enough ex pe ri e n ce to make any specific re co m m e n d at i o n s on this appro a c h .
Formulation Characterization
In order to chara cte ri ze the release from the dosage fo rm adequate l y,it is re cog n i zed that a d rug release profile should be generate d,in which release (dissolution) values are dete rmined as a f u n ction of time.This multipo i nt chara cte ri z at i o n has been in place for modified release dosage fo rms for some time and is also re commended fo r s l ower dissolving immediate release prod u ct s. Be cause many of the dosage fo rms discussed here a re co m p l ex in te rms of co m position and re l e a s e m e c h a n i s m ,t h ey will also re q u i re a multipo i nt dru g release test to chara cte ri ze release from the dru g p rod u ct in general and to test for possible alte rations in the release profile during sto ra g e.Mu l t ipo i nt tests may also be needed for batch re l e a s e testing in order to prove a good batc h -to -b atc h co n s i s te n cy.Ty p i cal cases where multipo i nt te s t s a re likely to be needed include tra n s d e rm a l p atc h e s,semisolid pre p a rat i o n s,chewing gums, 
